SRC signaling is crucial in the growth of synovial sarcoma cells

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2518-2528

  Michels, Sebastian ^a,b   Trautmann, Marcel ^a   Sievers, Elisabeth ^a   Kindler, Dagmar ^a   Huss, Sebastian ^a   Renner, Marcus ^d   Friedrichs, Nicolaus ^a   Kirfel, Jutta ^b   Steiner, Susanne ^b   Endl, Elmar ^c   Wurst, Peter ^c   Heukamp, Lukas ^a   Penzel, Roland ^d   Larsson, Olle ^e   Kawai, Akira ^f   Tanaka, Shinya ^g   Sonobe, Hiroshi ^h   Schirmacher, Peter ^d   Mechtersheimer, Gunhild ^d   Wardelmann, Eva ^a   Buttner, Reinhard ^a   Hartmann, Wolfgang ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Departments of Pathology   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Chungoku Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; DASATINIB; DOXORUBICIN; FOCAL ADHESION KINASE 1; HYBRID PROTEIN; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SS18 SSX FUSION PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MICE; MITOSIS; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REPRESSOR PROTEINS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TRANSLOCATION, GENETIC; TUMOR BURDEN; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876951877     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3023     Document Type: Article

References (40)

1. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001;30:1-14.
2. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, et al. The synovial sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006;66:9474-82.
3. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006;25:1042-52.
4. Raney RB. Synovial sarcoma in young people: Background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 2005;27:207-11.
5. Demetri GD. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin Oncol 2001;28:19-26.
6. Sawyers CL. Imatinib GIST keeps finding new indications: Successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol 2002;20: 3568-9.
7. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103:830-8.
8. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Res 1999;59:3588-91.
9. Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, et al. Phosphatidylinositol-30-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011;129:1564-75.
10. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-8.
11. Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005;331:1-14.
12. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene 2000;19:5620-35.
13. Cole PA, Shen K, Qiao Y, Wang D. Protein tyrosine kinases Src and Csk: A tail's tale. Curr Opin Chem Biol 2003;7:580-5.
14. Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux JF, et al. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 2010;29: 1303-15.
15. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000;275:41439-46.
16. Kunte DP, Wali RK, Koetsier JL, Hart J, Kostjukova MN, Kilimnik AY, et al. Down-regulation of the tumor suppressor gene C-terminal Src kinase: An early event during premalignant colonic epithelial hyperproliferation. FEBS Lett 2005;579:3497-502.
17. Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 2007;67:10129-37.
18. Huveneers S, Danen EH. Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci 2009;122:1059-69.
19. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: A regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19:5606-13.
20. Friedrichs N, Kuchler J, Endl E, Koch A, Czerwitzki J, Wurst P, et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008;216:428-39.
21. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 2004;204:105-13.
22. Watanabe T, Tsuda M, Makino Y, Ichihara S, Sawa H, Minami A, et al. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol Cancer Res 2006;4:499-510.
23. Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, et al. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: A gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 2002;62:3861-7.
24. Xie Y, Tornkvist M, Aalto Y, Nilsson G, Girnita L, Nagy B, et al. Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 2003;22:7628-31.
25. Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, et al. Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest 1992;67:498-505.
26. Kuchler J, Hartmann W, Waha A, Koch A, Endl E, Wurst P, et al. p75 (NTR) induces apoptosis in medulloblastoma cells. Int J Cancer 2010;128:1804-12.
27. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci U S A 2001;98: 3843-8.
28. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: A potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006;66:6919-27.
29. Webb JL, ed. Enzymes and metabolic inhibitors. Vol 1. New York, NY: Academic Press; 1963.
30. Cam WR, Masaki T, Shiratori Y, Kato N, Ikenoue T, Okamoto M, et al. Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma. Cancer 2001;92: 61-70.
31. Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, et al. PDGF receptor alpha is an alternative mediator of rapamycininduced Akt activation: Implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012;72:4515-25.
32. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
33. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
34. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14: 5749-58.
35. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009;69:6216-22.
36. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
37. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005;10:1041-7.
38. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4: 470-80.
39. Arai R, Tsuda M, Watanabe T, Ose T, Obuse C, Maenaka K, et al. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo. Eur J Cancer 2012;48:2417-30.
40. Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, et al. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res 2009;7:1582-92.